论文部分内容阅读
目的观察FOLFOX4化疗方案治疗晚期结直肠癌的临床疗效及其毒副反应。方法 53例晚期结直肠癌患者采用FOLFOX4方案化疗,每2周为1个周期,治疗4个周期后按WHO实体瘤疗效判定标准评价疗效及毒副反应。结果总有效(CR+PR)率为56.6%,其中结肠癌总有效率为54.2%,直肠癌总有效率58.6%,两组比较差异无统计学意义(P>0.05),中位缓解时间6.7个月,中位生存期13.7个月,1年生存率为56.0%。毒副反应主要为胃肠道反应、末鞘神经毒性、骨髓抑制及静脉炎等,对症治疗均能耐受。结论 FOLFOX4方案治疗晚期结直肠癌患者有提高总生存率的趋势,耐受性较好,疗效较满意,有临床应用价值。
Objective To observe the clinical efficacy and toxicity of FOLFOX4 chemotherapy for advanced colorectal cancer. Methods Fifty-three patients with advanced colorectal cancer were treated with FOLFOX4 regimen every two weeks for one cycle. After four cycles of treatment, the curative effect and adverse reactions were evaluated according to the criteria of WHO solid tumors. Results The total effective rate (CR + PR) was 56.6%. The total effective rate of colon cancer was 54.2% and the total effective rate of rectal cancer was 58.6%. There was no significant difference between the two groups (P> 0.05), and the median effective time was 6.7 Month, the median survival of 13.7 months, 1-year survival rate was 56.0%. Toxic and side effects mainly gastrointestinal reactions, end sheath neurotoxicity, bone marrow suppression and phlebitis, symptomatic treatment can tolerate. Conclusion The FOLFOX4 regimen has the tendency to improve the overall survival rate in patients with advanced colorectal cancer. The tolerability is better, the effect is satisfactory, and it has clinical value.